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Effects of Formalin-Inactivated Respiratory Syncytial Virus (FI-RSV) in
the Perinatal Lamb Model of RSV
Abstract
Respiratory syncytial virus (RSV) is the most frequent cause of bronchiolitis in infants and children
worldwide. There are currently no licensed vaccines or effective antivirals. The lack of a vaccine is partly due to
increased caution following the aftermath of a failed clinical trial of a formalin-inactivated RSV vaccine (FI-
RSV) conducted in the 1960’s that led to enhanced disease, necessitating hospitalization of 80% of vaccine
recipients and resulting in two fatalities. Perinatal lamb lungs are similar in size, structure and physiology to
those of human infants and are susceptible to human strains of RSV that induce similar lesions as those
observed in infected human infants. We sought to determine if perinatal lambs immunized with FI-RSV
would develop key features of vaccine-enhanced disease. This was tested in colostrum-deprived lambs
immunized at 3–5 days of age with FI-RSV followed two weeks later by RSV infection. The FI-RSV-
vaccinated lambs exhibited several key features of RSV vaccine-enhanced disease, including reduced RSV
titers in bronchoalveolar lavage fluid and lung, and increased infiltration of peribronchiolar and perivascular
lymphocytes compared to lambs either undergoing an acute RSV infection or naïve controls; all features of
RSV vaccine-enhanced disease. These results represent a first step proof-of-principle demonstration that the
lamb can develop altered responses to RSV following FI-RSV vaccination. The lamb model may be useful for
future mechanistic studies as well as the assessment of RSV vaccines designed for infants.
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Abstract
Respiratory syncytial virus (RSV) is the most frequent cause of bronchiolitis in infants and children worldwide. There are
currently no licensed vaccines or effective antivirals. The lack of a vaccine is partly due to increased caution following the
aftermath of a failed clinical trial of a formalin-inactivated RSV vaccine (FI-RSV) conducted in the 1960’s that led to enhanced
disease, necessitating hospitalization of 80% of vaccine recipients and resulting in two fatalities. Perinatal lamb lungs are
similar in size, structure and physiology to those of human infants and are susceptible to human strains of RSV that induce
similar lesions as those observed in infected human infants. We sought to determine if perinatal lambs immunized with FI-
RSV would develop key features of vaccine-enhanced disease. This was tested in colostrum-deprived lambs immunized at
3–5 days of age with FI-RSV followed two weeks later by RSV infection. The FI-RSV-vaccinated lambs exhibited several key
features of RSV vaccine-enhanced disease, including reduced RSV titers in bronchoalveolar lavage fluid and lung, and
increased infiltration of peribronchiolar and perivascular lymphocytes compared to lambs either undergoing an acute RSV
infection or naı¨ve controls; all features of RSV vaccine-enhanced disease. These results represent a first step proof-of-
principle demonstration that the lamb can develop altered responses to RSV following FI-RSV vaccination. The lamb model
may be useful for future mechanistic studies as well as the assessment of RSV vaccines designed for infants.
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Introduction
Respiratory syncytial virus (RSV) is a common cause of acute
lower respiratory infection and is the leading cause of infantile
bronchiolitis worldwide [1,2]. Premature infants, immunocom-
promised individuals and the elderly are at increased risk for
severe infection and hospitalization. RSV vaccine development
has been hampered since the 1960s when a clinical trial of a
formalin-inactivated alum-precipitated RSV vaccine (FI-RSV)
resulted in enhanced disease, two deaths, and hospitalization of
80% of the FI-RSV-vaccinated subjects [3–5]. Caution stem-
ming from this incident has led to the development of animal
models that mimic the FI-RSV vaccine-induced immunologic
and pulmonary responses that follow RSV infection. Models
have been developed in several species including BALB/c mice,
Bonnet monkeys, macaques, Cotton rats, and cattle [6–13].
Much has been learned from these models with regard to the
mechanistic basis underlying this enhanced host response, and
the growing number of animal models that can mimic this
condition suggests that the mechanism(s) may be universal
across species.
Perinatal lambs have been increasingly used to study RSV
pathogenesis, immunologic responses, and therapeutic strategies
[14]. The lamb lung has several critical features conducive to
modeling RSV infection in human infants, including similarities
in branching patterns, numbers of Clara cells, cellular develop-
ment, and innate immune responses. Perinatal lambs are also
susceptible to human strains of RSV, develop similar lesions to
human infants, and disease severity in lambs is increased in
preterm compared to term and older lambs–as in humans [14–
18]. Lambs can be born preterm and survive for RSV
experimentation and therefore represent one of the few animal
models that can be used for true comparisons to RSV disease in
human infants born preterm. This is important because preterm
birth is a leading risk factor for increased susceptibility to RSV-
induced disease and hospitalization [1,2]. Also, newborn lambs
(preterm and term) can be deprived of colostrum thereby
allowing studies lacking potential confounding effects of
maternal immunoglobulin. It was our hypothesis that perinatal
lambs vaccinated with FI-RSV would develop key features of
the vaccine-enhanced disease previously observed in human
infants. To determine the extent to which FI-RSV vaccination
may alter clinical, pathologic, and immunologic responses in
lambs, newborn lambs were vaccinated with a single dose of FI-
RSV, challenged two weeks later with RSV for six days, then
necropsied and assessed for clinical and pulmonary responses/
parameters at six days following infection.
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Results
Clinical Findings, Bronchoalveolar Lavage Fluid Viral
Titers, Viral RNA Levels and Viral Antigen
There were no significant differences between RSV-infected
lambs in terms of temperature, heart rate, body weight, respiratory
rate, and cellular composition of the bronchoalveolar lavage fluid
(BALF) according to scoring criteria we have used previously in
newborn and preterm lambs [15,16,17,18]. Sera from the FI-RSV
vaccinated group had significantly higher neutralizing antibody
titers than the control vaccine group, (p,0.05; Mann-Whitney
test) (Fig. 1).
FI-RSV vaccinated mice exhibit reduced viral titers in the lung
following RSV challenge [3,11,13]. Consistent with FI-RSV
vaccination providing modest protection in mice, immunized
lambs infected with RSV had significantly reduced (P,0.05) viral
titers in the BALF (Fig. 2) compared to lambs that received mock
vaccine. Viral titers in BALF from mock-vaccinated lambs reached
11906517 FFU/ml, whereas BALF titers from FI-RSV lambs
averaged less than 5 FFU/ml. Similarly, lambs vaccinated with FI-
RSV and infected with RSV showed significantly reduced
(P,0.05) RSV mRNA levels in lung tissue by RT-qPCR analysis
(Fig. 3) compared to lambs that received a mock vaccine. Mock-
vaccinated lambs averaged 35,00564770 RSV copies/mg lung
tissue whereas FI-RSV-vaccinated lambs averaged less than
3,95061540 RSV copies/mg lung tissue. In both bronchi/
bronchioles and alveoli, lambs vaccinated with FI-RSV and
infected with RSV demonstrated significantly reduced (P,0.05)
RSV antigen (Fig. 4) compared to lambs that received a mock
vaccine following RSV infection. Bronchi and bronchioles had a
score of 7.361.78 in mock-vaccinated lambs compared to RSV
antigen levels of 0.6760.22 in FI-RSV immunized lambs.
Similarly, alveoli had a score of 12.163.12 for RSV antigen in
mock-vaccinated lambs compared to a score of 3.061.05 in FI-
RSV-vaccinated lambs. In summary, FI-RSV vaccination reduced
RSV titers in BALF as well as RSV mRNA levels, and RSV
antigen levels in the lung tissue.
Histopathology
FI-RSV vaccinated children that died following a natural RSV
infection exhibited bronchopneumonia, atelectasis, emphysema,
dense lymphocytic and other mononuclear infiltrates around small
(distal) bronchi, bronchioles, and involved alveoli [4]. In lambs,
lesions present in those mock-vaccinated were identical to those
described previously in lambs inoculated with RSV M37 strain
and similar to those inoculated with RSV A2 and bovine RSV
(bRSV) strains [7,14,15,18]. Briefly, bronchioles contained infil-
trates of neutrophils along with accumulation of cell debris and
occasionally macrophages. Bronchiolar epithelium was eroded in
some areas and there were individual degenerate cells that were
slightly enlarged, partially detached from adjacent cells and had
pyknotic nuclei; some nearby cells were necrotic. In the lamina
propria and adventitia of bronchioles as well as multifocal small
and medium-sized blood vessels were infiltrates of lymphocytes
and plasma cells. There was moderate hypertrophy and hyper-
plasia of type II pneumocytes in alveoli, and alveolar lumens
contained variable amounts of cell debris as well as occasional
macrophages and moderate infiltrates of neutrophils. In lambs
vaccinated with FI-RSV and inoculated with RSV, lesions differed
significantly from those in mock-vaccinated lambs. In FI-RSV-
vaccinated lambs, the bronchiolar epithelial lesions and infiltrates
of neutrophils were present, but minimal with one to only several
neutrophils in a few bronchioles.
Lambs vaccinated with FI-RSV and infected with RSV had
significantly reduced histopathologic scores (Fig. 5) compared to
lambs receiving mock vaccine. Both bronchiolitis and consolida-
tion scores were reduced significantly (Fig. 5A, B). In mock-
vaccinated lambs, alveoli had a consolidation score of 1.360.23
while FI-RSV-vaccinated lambs gave a score of 0.160.06.
Figure 1. Serum neutralization titers of FI-RSV-vaccinated
lambs (FI-vaccinated) (n = 4) were significantly increased
compared to mock-vaccinated lambs (n=4) (*P,0.05). Error
bars = SEM.
doi:10.1371/journal.pone.0081472.g001
Figure 2. Bronchoalveolar lavage (BAL) titers of Control lambs
(no vaccine and no RSV), mock-vaccinated (MockVac) lambs
and FI-RSV-vaccinated lambs. FI-RSV-vaccinated lambs had signif-
icantly less RSV load compared to mock-vaccinated lambs. Control
lambs lacked RSV titers. Control n = 4; MockVac n = 4; FI-RSV n = 4. Error
bars = SEM, *P,0.05. FFU = focus-forming units per ml.
doi:10.1371/journal.pone.0081472.g002
Figure 3. RSV RNA M37 levels in mock-vaccinated (MockVac),
FI-RSV-vaccinated, and Control lambs as assessed by RT-qPCR.
FI-RSV-vaccinated lambs had significantly less RSV M37 RNA compared
to mock-vaccinated lambs. Control lambs lacked RSV RNA RT-qPCR
signal. Control n = 4; MockVac n = 4; FI-RSV n = 4. Error bars = SEM,
*P,0.05.
doi:10.1371/journal.pone.0081472.g003
FI-RSV Effects in Newborn Lambs
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Similarly, bronchiolitis scores were 1.1560.22 in mock-vaccinated
lambs as compared to 0.1560.09 in FI-RSV-vaccinated lambs.
Lambs vaccinated with FI-RSV and infected with RSV had
significantly increased (P,0.05) lymphocyte and plasma cell
infiltrates in airways and blood vessels (Figs. 6A, B) compared
to lambs receiving mock vaccine. Lymphocyte and plasma cell
infiltrates in the walls and adventitia of bronchioles, small bronchi,
and adventitia of small and medium-sized blood vessels were more
distinct and expanded due to increased cellularity. Lesion scores
for bronchioles (PbL scores) were 2.8560.13 in FI-RSV-vaccinat-
ed lambs and 160.16 in mock-vaccinated lambs. In blood vessels
(PvL scores), lesion scores were 2.560.17 in FI-RSV-vaccinated
lambs and 1.0560.13 in mock-vaccinated lambs. Multifocal
bronchioles had mild to moderate infiltrates of lymphocytes,
plasma cells and occasional macrophages in the tunica adventitia.
These infiltrates were also present in the lamina propria but to a
lesser degree (Fig. 7 A, B). Following RSV challenge, viral antigen
was more prevalent in mock-vaccinated lambs than lambs
vaccinated with FI-RSV (Fig. 7 C, D).
Discussion
FI-RSV-vaccinated lambs exhibited several key features of the
FI-RSV-enhanced disease observed previously in human infants.
These include the increased lymphocyte and plasma cell infiltrates
around bronchi and bronchioles [4,5] and pulmonary blood
vessels the lesions in bronchiolar airways (bronchiolitis) and alveoli
[4,5], and the development of a moderate serum neutralization
titer as well as significant reductions in BALF viral titers, viral
mRNA, and viral antigen levels in the lung tissue. These findings
demonstrate that the lamb develops altered responses to RSV
following FI-RSV-vaccination. This study represents a simplified
first attempt to assess the extent to which lambs may respond to
FI-RSV immunization; additional studies will be needed to further
optimize the model especially with regard to vaccine composition
and timing of delivery, and mechanistically in regard to Th2/IgE
responses.
The reason for the observed increase in lymphocytic and
plasmacytic infiltration is not fully understood. Immune responses
to FI-RSV have been shown to generate antibodies with low
avidity to RSV and a reduced capacity to induce strong TLR4
responses [19,20]. These effects, in addition to other unknown
factors, likely contribute to a dysregulated immune response that
triggers an exaggerated adaptive immune response with lympho-
cytes and plasma cells in large numbers and in a particular
location of the lung (airway and blood vessel adventitia). In these
locations, the cells produce a variety of chemokines, cytokines, and
other immune/inflammatory mediators that affect bronchiolar
epithelial cell activity and airway function, and the physical
presence of these cells likely also affects airway bronchoconstric-
tion and bronchodilation.
The lesions in bronchiolar airways and alveoli in mock-
vaccinated lambs were similar to those caused by RSV A2 and
bRSV in lambs and to those previously described in human infants
and cattle [5,7,13,21]. While vaccination with FI-RSV enhanced
lymphocyte and plasma cell infiltration around bronchioles and
blood vessels, bronchiolar airway and alveolar lesions were
reduced in lambs vaccinated with FI-RSV. The reduced
bronchiolar airway and alveolar lesions were associated with
reduced RSV titers in bronchoalveolar lavage fluid and reduced
RSV mRNA and RSV antigen. FI-RSV vaccination likely
provided some degree of protection against bronchiolar airway
and alveolar lesion development and helped to reduce viral
replication. The serum neutralization titer was increased signifi-
cantly compared to mock-vaccinated lambs and may have been
enough to reduce RSV replication which, in turn, contributed to
the observed reduction in bronchiolar and alveolar lesions. That is,
Figure 4. RSV antigen detected by immunohistochemistry
(IHC). Control bronchioles and alveoli (Control Br and Control Alv) lack
RSV antigen while bronchioles and alveoli of FI-RSV-vaccinated lambs
had significantly reduced levels of RSV antigen compared to mock-
vaccinated (MockVac) lambs. Control(s) n = 4; MockVac Br n = 4;
MockVac Alv n = 4; FI-RSV Br n = 4; FI-RSV Alv n = 4. Error bars = SEM,
*P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0081472.g004
Figure 5. Histopathologic lesions of consolidation (A) and;
bronchiolitis (B). Controls lacked lesions while mock-vaccinated
(MockVac) lambs had significantly increased consolidation and bron-
chiolitis scores compared to lambs vaccinated with FI-RSV. Control
n = 4; MockVac n = 4; FI-RSV n = 4. Error bars = SEM, *P,0.05, **P,0.01.
doi:10.1371/journal.pone.0081472.g005
FI-RSV Effects in Newborn Lambs
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the vaccine appeared to have a direct effect on viral load and an
additional effect on an atypical immune response.
Eosinophils were not a prominent feature in any region of the
lung. This lack of eosinophilic infiltration differs from findings in
FI-RSV-vaccinated children as some of the vaccinated children
exhibited eosinophilic infiltrates, as do some animal models
affected by viral and non-viral antigens [10,22–25]. On the other
hand, the lack of eosinophils is similar to previous studies in FI-
RSV-vaccinated cattle [7] and neutrophil infiltration was a
prominent finding in Cotton Rats [12]. Sheep and cattle are both
ruminants although the extent of similarities in their eosinophil
function has not been fully determined. The role of eosinophils in
the pathogenesis of FI-RSV lesions is not fully understood. It is
important to point out that lesions were assessed in this study at 6
days post-RSV inoculation and, at later timepoints, lesions may be
different. Also, the lambs were 3 weeks of age at the time of
necropsy/evaluation, and even older lambs may exhibit different
lesions as well. In addition, lambs in this study were inoculated
with RSV two weeks after vaccination and natural infection in
human infants occurred weeks to months after FI-RSV vaccina-
tion [4,5]. Furthermore, animal models challenge at 3 to 5 or more
weeks post FI-RSV vaccination [6–13]. The two-week timepoint
in this study was used because the lambs were colostrum-deprived
and there were concerns that the animals could be pre-disposed to
secondary bacterial or other microbial infections. This did not
occur in this study or in other studies we have on-going and
therefore, future studies will be able to assess RSV challenge 3 or
more weeks post-vaccination.
The lambs in this study lacked systemic signs of vaccine-
enhanced disease. In this study, only one vaccine dose was
administered, and only one timepoint was assessed after RSV
infection. Also, this study used RSV A2 strain to make the FI-RSV
vaccine while the lambs were challenged with a second strain,
RSV Memphis strain 37, demonstrating that RSV A2-based
vaccine preparation can yet result in FI-RSV-enhanced lesions. As
indicated, additional studies will further optimize the model and
can include: vaccine preparations that vary in protein content, use
vaccine strains homologous to the RSV challenge strain,
assessment of the effects of multiple vaccinations rather than a
single vaccination, vaccination of lambs older than 2–3 days of
age, determination of the kinetics of clinical, pathological and
immunological responses at various timepoints following chal-
lenge, assessment of various delivery methods and doses of RSV,
and the role of non-viral antigens. In addition, lambs can be born
preterm and subsequently infected with RSV (17) resulting in
disease severity and lesions that are increased compared to term
lambs. This increased disease severity is similar to the increased
susceptibility of preterm infants with severe RSV disease (4, 17).
The effects of FI-RSV vaccination on preterm lambs may induce
additional clinical, pathological and immunological responses.
This work demonstrates that FI-RSV vaccination of young
lambs results in features consistent with enhanced disease in
similarly vaccinated infants and other animal models. Because
lamb lung and the lamb model of RSV infection have extensive
similarities to human infants [14] the FI-RSV/lamb model may be
useful in clarifying some of the mechanisms underlying the
enhanced disease that occurs with RSV infection following FI-
RSV vaccination and, potentially, other innovative vaccine
formulations [28]. The model may be especially well-suited for
studies of the potential effects of maternal antibody on FI-RSV
vaccination since lambs can be deprived of colostrum (as in this
study) thereby avoiding confounding issues related to the presence
of maternal antibody [14]. The potential contribution of maternal
antibody to RSV vaccination-related lesions is important in the
development and testing of vaccines used in pregnant mothers and
newborns. Also, unlike some other animal models, lambs can be
born preterm, are susceptible to human strains of RSV, have
developmental features and lung structure and cellular composi-
tion similar to human infants, and thus can be used for additional
studies related to lung and immune system development.
Materials and Methods
Experimental Design
Colostrum-deprived lambs were acquired at 2–3 days of age
and received vaccine or mock vaccine (1 ml) intramuscularly at 3–
5 days of age. Three groups of lambs received the following: 1) no
vaccine followed by nebulized media (no RSV), 2) mock vaccine
followed by RSV inoculation (six ml of RSV M37 7.46106 FFU/
ml in media with 20% sucrose via nebulizer over 23 minutes); and
3) FI-RSV followed by RSV inoculation. Lambs were euthanized
and tissues were collected six days after RSV infection. This
timepoint was selected because it results in peak lesions in this
model [14,15]. Clinical parameters (temperature, respiration rate,
heart-rate and body weight) were logged daily, blood, broncho-
alveolar lavage (BAL) fluid and lung tissue were collected six days
Figure 6. Extent of lymphocyte and plasma cell infiltrates into
adventitia of bronchioles assessed by A. peribronchiolar
lymphocytic (PbL) scores. FI-RSV-vaccinated lambs had significantly
increased infiltrates compared to mock-vaccinated (MockVac) lambs.
Controls lacked lesions. Extent of lymphocyte and plasma cell infiltrates
into adventitia of blood vessels assessed by perivascular lymphocytic
(PvL) scores (B). FI-RSV-vaccinated lambs had significantly increased
infiltrates compared to control lambs. Mock-vaccinated lamb PvL
infiltrates were not significantly different from control lamb levels.
Controls lacked lesions. Control n = 4; MockVac n = 4; FI-RSV n = 4. Error
bars = SEM, *P,0.05, ***P,0.001.
doi:10.1371/journal.pone.0081472.g006
FI-RSV Effects in Newborn Lambs
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after RSV infection, and RSV and lesion parameters were
measured as described previously [15,16]. All animal experiments
were approved by the Institutional Animal Care and Use
Committee (IACUC) of Iowa State University.
FI-RSV Vaccine Preparation
A FI-RSV vaccine was made with RSV A2 strain as described
previously [15]. Briefly, FI-RSV was prepared from RSV A2-
infected Vero cells grown in OptiPROTM SFM media (Invitro-
gen, Carlsbad, CA). Virus-infected cells were removed by scraping
followed by sonication for eight 1-second pulses, and subsequently
centrifuged at 8006g for 10 minutes. Supernatant was inactivated
with 10% buffered formalin at 1:400 dilution for 72 hours at 37uC
followed by ultracentrifugation at 50,0006g for 1 hour at 4uC.
The pellet was resuspended in OptiPROTM SFM at 1:25 dilution
with 4 mg/ml of Imject Alum adjuvant (Thermo Fisher Scientific,
Waltham, MA). The solution was centrifuged at 10006g for 30
minutes at 4uC and the pellet was resuspended at 1:4 dilution in
OptiPROTM SFM (Gibco/Invitrogen). The FI-RSV preparation
was sonicated in a water-bath sonicator for 15 seconds on ice and
stored in amber glass vials at 4uC. An FI-mock vaccine was also
prepared using the same protocol from a lysate of Vero cells mock-
infected with PBS.
RSV Serum Neutralization Assay
Sera of lambs were heat inactivated (40 minutes at 56uC) and
added to DMEM with 5% heat inactivated normal sheep serum
(NSS) to yield a total concentration of serum of 10% and the
highest starting test serum concentration of 5%, or 1:20. The sera
were serially diluted in a two-fold series in DMEM 10% NSS. To
each well, 50 FFU were added and the serum was incubated at
37% for 1 hr. The sera were placed in a 96 well plate with HEp-2
cells and incubated for 1 hr at 37uC, 5% CO2, after which 100 ml
DMEM, 10% FBS were added and the plates were incubated for 5
days, then fixed with 3.7% formaldehyde in PBS, and counter-
stained with methylene blue. If the monolayer was intact, the
serum dilution was scored as neutralizing, whereas lysed mono-
layers were scored as non-neutralizing. A numerical value was
assigned to the neutralizing titer by multiplying the titer by 10, and
titers lower than 1:20 received a value of 1. A titer of 1:20 was
assigned a value of 2; 1:40 was assigned a value of 4. Statistical
significance was determined by the Mann-Whitney test.
Administration of Virus to Lambs by Nebulization
PARI SprintTM nebulizers were used to administer virus or
control media to each lamb. Three 2-ml aliquots of virus-
containing media or control media was administered to each
animal over the course of 23 minutes resulting in the total
inhalation of about 5 ml by each lamb. Preliminary studies showed
Figure 7. Lung of FI-RSV-vaccinated lamb with marked peribronchiolar lymphocytic infiltrates characterized by numerous, closely
packed lymphocytes and plasma cells and a bronchiole that is slightly dilated but lacking intralumenal neutrophils (A) andLung of
mock-vaccinated lamb with bronchiole containing neutrophils and relatively mild peribronchiolar lymphocytic infiltration
characterized by a few lymphocytes and occasional plasma cells there are somewhat dispersed and not densely associated (B).
Lung of FI-RSV-vaccinated lamb with marked peribronchiolar lymphocytic infiltrates and only a few cells containing RSV antigen (C). Lung of mock-
vaccinated lamb with increased viral antigen distribution in multifocal cells and intensity characterized by more intense staining (D). Bar = 150 mm.
doi:10.1371/journal.pone.0081472.g007
FI-RSV Effects in Newborn Lambs
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that the addition of 20% sucrose was protective of the virus
(manuscript submitted; Drew D. Grosz); therefore, the nebulate
contained 20% sucrose.
Tissue Collection and Viral Titers
After euthanasia the thorax was opened, lungs were removed,
gross lesions were scored as described previously [17,18] and
photographed in situ and ex vivo. Tissue samples were collected
from each lung lobe of all animals in the same manner. Briefly,
multiple samples from each lobe were snap-frozen in liquid
nitrogen for RNA isolation and subsequent reverse transcription
quantitative polymerase chain reaction (RT-qPCR), two samples
from each lobe were placed in tissue cassettes and put in 10%
neutral-buffered formalin (NBF) for histological and immunohis-
tochemical analysis, and two lung samples from each animal were
placed into cryomolds with CRYO-OCT Compound (Tissue-Tek,
Torrance, CA) then placed on dry-ice for transfer to 280uC
storage for future cryo-sectioning. After removal, percentage
parenchymal involvement was estimated for each lung lobe.
Percentages were converted to a number using the following scale:
0%=0, 1–9%=1, 10–39%=2, 40–69%=3, 70–100%=4.
Group averages were calculated for the gross lesion score.
Bronchoalveolar lavage fluid (BALF) viral titers were measured
for each lamb by flushing the excised right caudal lung lobe with
5 ml of cold modified Iscove’s media (42.5% Iscove’s modified
Dulbecco’s medium, 7.5% glycerol, 1% heat-inactivated FBS,
49% DMEM, and 5 mg/ml kanamycin sulfate) after which 1 ml of
the resulting BAL fluid was placed on ice for immediate use in our
standard infectious focus assay. For this, 1 ml BALF sample
collected from each lamb was applied to HEp-2 cells grown to
70% confluence in 12-well culture plates (Fisher Scientific,
Hanover, IL) in DMEM media (Mediatech, Inc., Manassas, VA)
supplemented to 10% with heat-inactivated fetal bovine serum
(FBS) (Atlanta Biologicals, Atlanta, GA) and 50 mg/ml kanamycin
sulfate (Invitrogen). Each sample was analyzed at full-strength and
at four additional serial-dilutions of 1:10, 1:100, 1:1,000 and
1:10,000. 200 ml of each diluted BALF sample was assessed in
duplicate. Overnight primary antibody (MAb to RSV Fusion
Protein, Clone: RSV 3216 (B016), Meridian Bioscience, Cincin-
nati, OH) incubation was followed by washing and secondary
antibody (Goat anti-Mouse Fab’ conjugated to AlexaFluor 488,
Invitrogen) incubation for 30 minutes. Plates were rinsed and
inspected for the presence of fluorescing foci of infection using the
FITC/GFP filter on an inverted fluorescence microscope (Olym-
pus CKX41, Center Valley, PA). Five or more fluorescing cells
were counted as single focal events. Aliquots of BALF in PBS from
accessory lobes were assessed for total nucleated cell count and
cytology. Counts were performed using the ADVIA 120TM
automated hematology analyzer (samples were diluted 1:2 in
isotonic saline prior to cell counting). Cytospin preparations of
BALF were created using a Shandon Cytospin 3. Modified
Wright’s was used to stain the slides and differential cell counts
(based on a 300 cell differential) were performed by a board
certified veterinary clinical pathologist blinded to the identity of all
samples.
Microscopic Lesion Evaluation and Scoring
A histologic score was determined by evaluating percent
consolidation and converting the observed percentage ranges to
a simple integer based on a consolidation scale used by our
laboratory previously (35, 36): 0% consolidation= 0, 1–9%
consolidation = 1, 10–39% consolidation = 2, 40–69% consolida-
tion= 3, 70–100% consolidation = 4. Group averages were calcu-
lated for the alveolar consolidation score.
Reverse Transcription Quantitative Polymerase Chain
Reaction (RT-qPCR) Measurement of RSV M37
Nucleoprotein mRNA
Tissues from right and left cranial, right and left middle, and
right and left caudal lung lobes (0.3–0.4 g of each) were
homogenized in TRIzol (Invitrogen), pooled in equal portions to
create a composite slurry for each animal, then adjusted to
0.091 g/ml with additional TRIzol. RNA isolation continued as
per manufacturer’s instructions (Invitrogen), followed by DNase
treatment (Ambion, TURBO DNase, Austin, TX) and 1:10
dilution with a combination of RNaseOUT (Invitrogen) and
ultrapure water (Millipore). NanoDrop (Thermo Fisher Scientific)
was used to assess each sample for simple RNA purity and total
RNA quantity (A260nm/A280nm all .1.95). Agilent Bioanalyzer
2100 analysis of total RNA prior to DNase treatment and dilution
routinely showed RIN values of .8.0. RT-qPCR was carried out
using One-Step Fast qRT-PCR Kit master mix (Quanta,
BioScience, Gaithersburg, MD) in a GeneAmp 5700 Sequence
Detection System (Applied Biosystems, Carlsbad, CA) with
PREXCEL-Q calculations [26,27]. Primers and probe for RSV
M37 nucleoprotein were designed with ABI Primer Express 2.0
based on RSV accession number M74568. Forward primer: 59-
GCTCTTAGCAAAGTCAAGTTGAACGA; reverse primer: 59-
TGCTCCGTTGGATGGTGTATT; hydrolysis probe: 59-
6FAM-ACACTCAACAAAGATCAACTTCTGTCATCCAGC-
TAMRA. Each 1:10-diluted total RNA sample was further diluted
so that each final RT-qPCR contained 0.784 ng total RNA/ml;
which was determined optimal by PREXCEL-Q [19,20].
Thermocycling conditions were 5 minutes at 50uC; 30 seconds
at 95uC; and 45 cycles of 3 seconds at 95uC and 30 seconds at
60uC. Samples and standards were assessed in duplicate and each
RT-qPCR quantification cycle (Cq) was converted to a relative
quantity (rQ) based on a standard curve using the following
equation: rQ=10((Cq2b)/m), where b and m are the y-intercept and
slope, respectively, from a sample mixture-derived standard curve
for RSV M37 nucleoprotein mRNA. The efficiency-corrected
delta Cq (EAMP
DCq) method was employed for RT-qPCR
quantification analysis. Results were normalized to total tissue
RNA loaded per reaction and identical for all reactions. No-RT
control reactions proved negative for RSV M37. RT-qPCR was
demonstrably free of inhibition based on PREXCEL-Q inhibitory
dilution threshold analysis [19,20].
Detection and Quantification of RSV Antigen by
Immunohistochemistry
Immunohistochemistry for detection, localization, and quanti-
fication of RSV antigen was performed on paraffin-embedded
tissues using a method similar to what has been described
previously [15–18], but with the following variations: instead of
Pronase E antigen retrieval, heated buffer antigen retrieval was
performed in TE-0.05% Tween 20, pH 9.0 in a pressure cooking
device (Decloaking ChamberTM Plus, Biocare Medical, Concord,
CA) using the factory default program (40 minutes with peak
temperature (125uC) at 18 minutes and cooling to 80uC in another
22 minutes. Initial blocking for 15 minutes with 3% bovine serum
albumin (BSA) (Fisher Scientific, Hanover, IL) in TBS-0.05%
Tween 20, pH 7.4 (TBS-tw) was followed by additional blocking
with 20% normal swine serum (NSS) (Gibco/Invitrogen) in TBS-
tw for 15 minutes. Primary polyclonal goat anti-RSV antibody
(EMD/Millipore/Chemicon, Billerica, MA) was applied (1.5
hours at 22uC) at a dilution of 1:500 in TBS-tw containing 10%
NSS and 3% BSA. After rinsing with TBS-tw, biotinylated rabbit
anti-goat secondary antibody (Kirkegaard-Perry Labs, Gaithers-
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burg, MD) diluted 1:300 in TBS-tw containing 10% NSS and 3%
BSA was applied (45 minutes), slides were rinsed, blocked with 3%
peroxide in TBS-tw (25 minutes), followed by streptavidin-
conjugated HRP (Invitrogen) diluted 1:200 in TBS-tw (30
minutes). Color was developed using Nova Red (Vector,
Burlingame, CA) for 90 seconds followed by water rinses,
counterstaining (Harris’ hematoxylin, 2 minutes), counter staining
with alkaline Scott’s water (1 minute), dehydration and cover-
slipped with Permount medium (Sigma, St. Louis, MO). Slides
(two lung samples) were scored: 20 unique 10X fields on each slide
were assessed for antigen staining and immunoreactive cells were
counted within bronchioles and alveoli. The number of cells
immunoreactive for RSV per field was then assigned a score
according to the following scale: 0 = 0, 1 = 1–10, 2= 11–39,
3 = 40–99, 4 =.100.
Statistical Analysis
Analyses were performed using GraphPad Prism 6 (GraphPad
Software Inc, La Jolla, CA). All post-mortem data was assessed by
one-way ANOVA followed by Tukey’s post-test. All clinical data
were assessed by two-way ANOVA, and cumulative weight
change was additionally assessed by one-way ANOVA followed
by Tukey’s post-test. Serum neutralization titers were assessed by
the Mann-Whitney test.
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